Suzanne L Epstein

List of Publications by Year
in descending order

58 papers	3,526 citations	236925 25 h-index	168389 53 g-index
58 all docs	58 docs citations	58 times ranked	3482 citing authors

#	Article	IF	Citations
1	Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies. Journal of Virology, 2022, 96, .	3.4	2
2	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. Journal of Virology, 2021, 95, .	3.4	7
3	Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice. Vaccine, 2021, 39, 4628-4640.	3.8	13
4	Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine. PLoS Pathogens, 2020, 16, e1008583.	4.7	22
5	The effect of respiratory viruses on immunogenicity and protection induced by a candidate universal influenza vaccine in mice. PLoS ONE, 2019, 14, e0215321.	2.5	5
6	Conventional influenza vaccines influence the performance of a universal influenza vaccine in mice. Vaccine, 2018, 36, 1008-1015.	3.8	7
7	Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen. Vaccine, 2018, 36, 4910-4918.	3.8	11
8	Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo. American Journal of Epidemiology, 2018, 187, 2603-2614.	3.4	27
9	Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic. Open Forum Infectious Diseases, 2017, 4, ofx023.	0.9	6
10	Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in Mice. PLoS ONE, 2016, 11, e0153195.	2.5	14
11	First flu is forever. Science, 2016, 354, 706-707.	12.6	33
12	Mucosal Immunization with a Candidate Universal Influenza Vaccine Reduces Virus Transmission in a Mouse Model. Journal of Virology, 2014, 88, 6019-6030.	3.4	49
13	Survey of Human Antibody Responses to Influenza Virus Matrix Protein 2 by Use of a Sensitive Flow Cytometric Method. Journal of Infectious Diseases, 2014, 209, 975-977.	4.0	4
14	Continuing to strengthen FDA's science approach to emerging technologies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 594-599.	3.3	14
15	Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus. PLoS ONE, 2013, 8, e55435.	2.5	43
16	Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3173-3177.	7.1	60
17	T-Cell Immune Responses and Asymptomatic H5N1 Influenza Infection. Journal of Infectious Diseases, 2012, 205, 4-6.	4.0	5
18	Cold-Adapted Influenza and Recombinant Adenovirus Vaccines Induce Cross-Protective Immunity against pH1N1 Challenge in Mice. PLoS ONE, 2011, 6, e21937.	2.5	42

#	Article	IF	Citations
19	Intranasal Administration of Adeno-associated Virus Type 12 (AAV12) Leads to Transduction of the Nasal Epithelia and Can Initiate Transgene-specific Immune Response. Molecular Therapy, 2011, 19, 1990-1998.	8.2	18
20	TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection. Journal of Immunology, 2011, 186, 2422-2429.	0.8	167
21	Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine, 2010, 28, 5817-5827.	3.8	30
22	Cross-protective immunity to influenza A viruses. Expert Review of Vaccines, 2010, 9, 1325-1341.	4.4	105
23	Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses. PLoS ONE, 2010, 5, e13162.	2.5	110
24	Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine, 2009, 27, 6512-6521.	3.8	114
25	Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: Cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine, 2008, 26, 2062-2072.	3.8	70
26	Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1. Emerging Infectious Diseases, 2007, 13, 426-435.	4.3	256
27	Prior H1N1 Influenza Infection and Susceptibility of Cleveland Family Study Participants during the H2N2 Pandemic of 1957: An Experiment of Nature. Journal of Infectious Diseases, 2006, 193, 49-53.	4.0	288
28	Critical Path Workshop on the Development of Cellular and Gene Therapy Products. Molecular Therapy, 2005, 12, 5-8.	8.2	2
29	Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine, 2005, 23, 5404-5410.	3.8	254
30	Protection against lethal influenza virus challenge by RNA interference<i>in vivo</i>. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8682-8686.	7.1	366
31	Control of influenza virus infection by immunity to conserved viral features. Expert Review of Anti-Infective Therapy, 2003, 1, 627-638.	4.4	46
32	DNA Vaccine Expressing Conserved Influenza Virus Proteins Protective Against H5N1 Challenge Infection in Mice. Emerging Infectious Diseases, 2002, 8, 796-801.	4.3	153
33	Susceptibility and immunity to influenza A strains in Igâˆ'/âˆ'mice. International Congress Series, 2001, 1219, 327-332.	0.2	0
34	Vaccination with DNA encoding conserved influenza viral proteins. International Congress Series, 2001, 1219, 905-910.	0.2	1
35	Heterosubtypic Immunity to Influenza A Virus in Mice Lacking IgA, All Ig, NKT Cells, or Î³Î´ T Cells. Journal of Immunology, 2001, 166, 7437-7445.	0.8	127
36	Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T lymphocytes: either CD4+ or CD8+ T cells can promote survival and recovery after challenge. International Immunology, 2000, 12, 91-101.	4.0	67

#	Article	IF	Citations
37	FDA comments on phase I clinical trials without vector biodistribution data. Nature Genetics, 1999, 22, 326-326.	21.4	6
38	Mice Deficient in Nuclear Factor (NF)-Î°B/p52 Present with Defects in Humoral Responses, Germinal Center Reactions, and Splenic Microarchitecture. Journal of Experimental Medicine, 1998, 187, 147-159.	8.5	412
39	Critical Roles for the Bcl-3 Oncoprotein in T Cellâ€"Mediated Immunity, Splenic Microarchitecture, and Germinal Center Reactions. Immunity, 1997, 6, 479-490.	14.3	177
40	Interferon (IFN) Consensus Sequence-binding Protein, a Transcription Factor of the IFN Regulatory Factor Family, Regulates Immune Responses In Vivo through Control of Interleukin 12 Expression. Journal of Experimental Medicine, 1997, 186, 1535-1546.	8.5	153
41	FDA research. Nature Medicine, 1997, 3, 816-816.	30.7	0
42	Mouse Monoclonal Antibodies to Human Immunodeficiency Virus Glycoprotein 120 Generated by Repeated Immunization with Glycoprotein 120 from a Single Isolate, or by Sequential Immunization with Glycoprotein 120 from Three Isolates. Hybridoma, 1995, 14, 235-242.	0.6	19
43	Recombinant human CD4 elicits antibody responses different in epitope specificity from those that cellular CD4 elicits. Molecular Immunology, 1993, 30, 765-773.	2.2	5
44	Letter to the editor. Molecular Immunology, 1991, 28, 193.	2.2	1
45	Anti-Leu3a Induces Combining Site-Related Anti-idiotypic Antibody Without Inducing Anti-HTV Activity. AIDS Research and Human Retroviruses, 1991, 7, 55-63.	1.1	7
46	Regulatory Concerns in Human Gene Therapy. Human Gene Therapy, 1991, 2, 243-249.	2.7	23
47	Induction of antigen-specific immunity with monoclonal anti-idiotypic antibodiesin vivo: differences in potency and comparison of immunochemical. European Journal of Immunology, 1989, 19, 2361-2365.	2.9	6
48	Eight new MHC recombinant strains defining at least six H-2 haplotypes. Immunogenetics, 1986, 24, 135-138.	2.4	8
49	Idiotypic Manipulation of the Immune Response to Transplantation Antigens. Immunological Reviews, 1986, 90, 5-28.	6.0	22
50	A cell surface ELISA in the mouse using only poly-l-lysine as cell fixative. Journal of Immunological Methods, 1985, 76, 63-72.	1.4	50
51	Characterization of a dominant anti-Ia idiotype using the Ia mutant mouse strain B6.C-H-2bm12. Molecular Immunology, 1985, 22, 417-426.	2.2	1
52	The I-J dilemma: new developments. Trends in Immunology, 1984, 5, 94-95.	7.5	5
53	Expression of Anti-MHC Idiotypes in Immune Responses. , 1984, , 279-297.		1
54	Idiotypes of Anti-MHC Monoclonal Antibodies. , 1984, , 243-269.		5

#	Article	IF	Citations
55	The presence of a common idiotype in anti-H-2 immune sera as detected by anti-idiotype to a monoclonal anti-H-2 antibody. European Journal of Immunology, 1983, 13, 13-18.	2.9	10
56	Idiotypes of Anti-Major Histocompatibility Complex Antibodies. Annals of the New York Academy of Sciences, 1983, 418, 265-271.	3.8	3
57	Induction of anti-Hâ€“2 antibodies without alloantigen exposure by in vivo administration of anti-idiotype. Nature, 1981, 291, 233-235.	27.8	71
58	Immunoglobulin classes and subclasses in alloantisera to mouse thymocyte surface antigens. Immunogenetics, 1979, 8, 517-528.	2.4	3